Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
Holding IOBT?
Track your performance easily
IOBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $2.10
Previous Close$1.05
Volume430.71K
Average Volume (3M)461.31K
Market Cap
$69.17M
Enterprise Value-$29.42M
Total Cash (Recent Filing)$100.75M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding65,880,914
10 Day Avg. Volume378,127
30 Day Avg. Volume461,315
Standard Deviation0.23
R-Squared0.00854
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.72
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$9.00Price Target Upside882.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
IO Biotech News
PremiumCompany Announcements
IO Biotech’s Promising Phase 3 Cancer Vaccine Trial Advances
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsIOBT's NSCLC data is described as promising with a higher response rate compared to historical studies.
EfficacyThe disease control rate was 80.6%, indicating a strong response among the cohort.
Response RateThe overall response rate of 55% demonstrates continued benefit on top of pembro alone.
Bears Say
Efficacy ConcernsThe Ph3 study of IO102-IO103 + pembro in 1L advanced melanoma did not meet the very high bar for success (P<0.005) on the interim ORR analysis, as expected.
Safety ProfileThe safety profile showed Grade 3-4 treatment-related adverse events in 24% of patients, which is slightly higher than some comparable studies.
Study Outcome UncertaintyThe chances of the interim analysis hitting are low given the high stats bar and leave a positive outcome as upside.
---
Ownership Overview
28.02% Insiders
0.72% Mutual Funds
5.09% Other Institutional Investors
66.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.73 and its highest was $2.10 in the past 12 months.
What is IO Biotech’s market cap?
Currently, no data Available
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Mar 27, 2025 which is in 135 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Aug 13, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.03.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 17.692%.
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at N/A.
---
IO Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (882.43% Upside)
$9.00 (882.43% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.5%
Last 30 Days ▲ 18.9%
Last 30 Days ▲ 18.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.14%
12-Months-Change
Fundamentals
Return on Equity
-87.66%
Trailing 12-Months
Asset Growth
-5.18%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
---
IOBT Stock 12 Month Forecast
Average Price Target
$9.00
▲(882.43% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kala Pharmaceuticals
―
Oncternal Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-20.56%
reiterated a buy rating 21 hours ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -20.56% per trade.
---